Wang Y, Lu LC, Guan Y, et al. Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance. Exp Hematol Oncol. 2021;10:45.

Article  PubMed  PubMed Central  Google Scholar 

Hoshino T, Naganuma A, Furusawa A, et al. A case of conversion hepatectomy for huge hepatocellular carcinoma with adrenal metastasis and vascular invasion after atezolizumab-bevacizumab treatment. Clin J Gastroenterol. 2022;15:776–83.

Article  PubMed  Google Scholar 

Hidaka Y, Tomita M, Desaki R, et al. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report. World J Surg Oncol. 2022;20:228.

Article  PubMed  PubMed Central  Google Scholar 

Fukunaga A, Takata K, Itoh S, et al. Complete tumor necrosis confirmed by conversion hepatectomy after atezolizumab-bevacizumab treatment for advanced-stage hepatocellular carcinoma with lung metastasis. Clin J Gastroenterol. 2023;16:224–8.

Article  PubMed  Google Scholar 

Miyata T, Sugi K, Horino T, et al. Conversion surgery after atezolizumab plus bevacizumab for primary and peritoneal metastasis after hepatocellular carcinoma rupture. Anticancer Res. 2023;43:943–7.

Article  PubMed  Google Scholar 

Kurisaki K, Soyama A, Hara T, et al. Pathologic complete response after chemotherapy with atezolizumab plus bevacizumab for hepatocellular carcinoma with tumor thrombus in the main portal trunk. Dig Surg. 2023;40:84–9.

Article  CAS  PubMed  Google Scholar 

Tsunemitsu R, Tabuchi M, Sakamoto S, et al. Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy. Surg Case Rep. 2023;9:93.

Article  PubMed  PubMed Central  Google Scholar 

Hsu H-M, Tsai H-I, Lee W-C, Wang C-C, Ming-Chin Y, Lin S-M, Lin C-Y, Chi-Huan W, Lee C-W. Theextended surgical concepts for hepatocellular carcinoma in the era of immune checkpoint inhibitors. J Hepatocell Carcinoma. 2023;24(10):1873–80.

Article  Google Scholar 

Kudo M, Aoki T, Ueshima K, et al. Upfront systemic therapy with subsequent curative conversion for intermediate-stage hepatocellular carcinoma: atezolizumab+bevacizumab curative conversion (ABC conversion) therapy. KanTanSui. 2021;83:475–783.

Google Scholar 

Kudo M. A novel treatment strategy for patients with intermediate-stage HCC who are not suitable for TACE: upfront systemic therapy followed by curative conversion. Liver Cancer. 2021;10:539–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Niizeki T, Tokunaga T, Takami Y, et al. Comparison of efficacy and safety of atezolizumab plus bevacizumab and lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a propensity score matching analysis. Target Oncol. 2022;17:643–53.

Article  PubMed  PubMed Central  Google Scholar 

Shimose S, Iwamoto H, Shirono T, et al. The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Cancer Med. 2023;12:12325–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.

Article  CAS  PubMed  Google Scholar 

Pfister D, Núñez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:450–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu AX, Abbas AR, de Galarreta MR, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022;28:1599–611.

Article  CAS  PubMed  Google Scholar 

Espinoza M, Muquith M, Lim M, et al. Disease etiology and outcomes after atezolizumab plus bevacizumab in hepatocellular carcinoma: post-hoc analysis of IMbrave150. Gastroenterology. 2023;165:286-288.e4.

Article  CAS  PubMed  Google Scholar 

Brown TJ, Mamtani R, Gimotty PA, et al. Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis. J Cancer Res Clin Oncol. 2023;149:2345–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rimini M, Rimassa L, Ueshima K, et al. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO Open. 2022;7:100591.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gougis P, Jochum F, Abbar B, et al. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective. eClinicalMedicine. 2024;70:102536.

Article  PubMed  PubMed Central  Google Scholar